Adjuvant intralesional and systemic Corynebacterium parvum immunotherapy for surgically treated head and neck cancer.

Published on Jan 1, 1978in Surgical forum
Beatty Jd1
Estimated H-index: 1
(MCV: VCU Medical Center),
Terz Jj1
Estimated H-index: 1
+ 3 AuthorsAlan M. Kaplan12
Estimated H-index: 12
Source
Abstract
References0
Newest
Cited By2
Newest
#1Alyson Bessell (UoB: University of Bristol)H-Index: 3
#2Anne-Marie Glenny (University of Manchester)H-Index: 56
Last. Helen V Worthington (University of Manchester)H-Index: 93
view all 10 authors...
BACKGROUND: Surgery is an important part of the management of oral cavity cancer with regard to both the removal of the primary tumour and removal of lymph nodes in the neck. Surgery is less frequently used in oropharyngeal cancer. Surgery alone may be treatment for early stage disease or surgery may be used in combination with radiotherapy, chemotherapy and immunotherapy/biotherapy. There is variation in the recommended timing and extent of surgery in the overall treatment regimens of people wi...
92 CitationsSource
#1Gregory T. WolfH-Index: 1
Overall survival rates for patients with advanced head and neck cancer remain dismal despite intensive combined modality treatment approches using surgery, radiation therapy and chemotherapy. It is well established that single modality treatment strategies employing surgery or radiation therapy for small, locally confined tumors achieve 5-year survival rates of 70–90%. However, in patients with extensive primary tumors or regional metastases, the 5-year survival rates range from 0–60%. These gen...
9 CitationsSource